Amundi
ALLO icon

Amundi’s Allogene Therapeutics ALLO Stock Holding History

Amundi’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,011
Closed -$21.9K – 2147
2024
Q3 		$21.9K Hold
8,011
– – ﹤0.01% 1903
2024
Q2 		$16.7K Buy
+8,011
New +$23.6K ﹤0.01% 1858
2022
Q2 		– Sell
-5,076
Closed -$46K – 1659
2022
Q1 		$46K Hold
5,076
– – ﹤0.01% 1541
2021
Q4 		$61K Hold
5,076
– – ﹤0.01% 1601
2021
Q3 		$130K Hold
5,076
– – ﹤0.01% 1491
2021
Q2 		$132K Buy
+5,076
New +$145K ﹤0.01% 1446

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Amundi's ALLO Position: Q4 2024 in Review

Amundi sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 8,011 shares — an estimated $21.9K sold.

Amundi first reported a position in ALLO in Q2 2021 and held it in 6 quarters. The position peaked at $132K in Q2 2021. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

  • Amundi reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Amundi sold 8,011 Allogene Therapeutics shares in Q4 2024, an estimated $21.9K.
  • Amundi first reported a position in Allogene Therapeutics in Q2 2021 and held it in 6 quarters.
  • Amundi's Allogene Therapeutics position peaked at $132K in Q2 2021.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Amundi's 13F filing for Q4 2024, filed 7 Feb 2025.